What is GSK acquiring from RAPT Therapeutics?

GSK is acquiring RAPT Therapeutics and its lead drug candidate, ozureprubart, which targets severe food allergies.

When will GSK's new allergy drug be available?

The drug, ozureprubart, is expected to launch by 2031 if clinical trials are successful.

How does ozureprubart work for food allergies?

Ozureprubart is designed to bind to and neutralize IgE, a key driver of allergic reactions to foods like nuts, milk, and eggs.

Home / Business and Economy / GSK Bets Big on Allergy Cure

GSK Bets Big on Allergy Cure

20 Jan

•

Summary

GSK acquired RAPT Therapeutics for $2.2 billion.
A new drug, ozureprubart, targets severe food allergies.
Potential blockbuster drug could launch by 2031.

GSK has announced a significant $2.2 billion acquisition of RAPT Therapeutics, a US-based biotech firm. This strategic move bolsters GSK's pipeline with ozureprubart (Ozu), a promising drug designed to combat severe food allergies.

Ozureprubart is an innovative, long-acting therapy currently in mid-stage clinical trials. It targets IgE, a crucial component in triggering allergic reactions to common foods like nuts, milk, and eggs.

Data from ongoing trials are anticipated next year, with large-scale studies planned for the second half of 2027. If successful, ozureprubart could be available by 2031, potentially generating over $1 billion annually for GSK.